No-Needle weight loss patch enters human testing

NCT ID NCT07673900

Recruiting now Disease control Sponsor: Terrestrial Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-stage study tests a new way to deliver semaglutide—a drug used for weight management—using a small, needle-free patch that sticks to the skin. The patch, called VX-201, aims to provide the same benefits as injections without the need for needles. The trial includes healthy adults who are overweight or obese and compares the patch to standard semaglutide injections to see if it is safe and how well the drug enters the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (delivered via microneedle patch)
What this could lead to: If successful, this could offer a needle-free alternative to daily or weekly injections for weight management, making treatment easier and more comfortable.
What could go wrong: This is an early Phase 1 study focused on safety and dosing, so it is too soon to know if the patch works as well as injections. Skin reactions or inconsistent drug absorption are possible risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND/OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND/OR OBESITY

Contacts and locations

Show contact details

Locations

Celerion Clinical Research
RECRUITING

Tempe, Arizona, 85283, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.